241 related articles for article (PubMed ID: 7814146)
1. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
Wels W; Beerli R; Hellmann P; Schmidt M; Marte BM; Kornilova ES; Hekele A; Mendelsohn J; Groner B; Hynes NE
Int J Cancer; 1995 Jan; 60(1):137-44. PubMed ID: 7814146
[TBL] [Abstract][Full Text] [Related]
2. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.
Schmidt M; McWatters A; White RA; Groner B; Wels W; Fan Z; Bast RC
Gynecol Oncol; 2001 Feb; 80(2):145-55. PubMed ID: 11161852
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor.
Wels W; Harwerth IM; Mueller M; Groner B; Hynes NE
Cancer Res; 1992 Nov; 52(22):6310-7. PubMed ID: 1358432
[TBL] [Abstract][Full Text] [Related]
5. A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor.
Schmidt M; Hynes NE; Groner B; Wels W
Int J Cancer; 1996 Feb; 65(4):538-46. PubMed ID: 8621240
[TBL] [Abstract][Full Text] [Related]
6. Biotechnological and gene therapeutic strategies in cancer treatment.
Wels W; Moritz D; Schmidt M; Jeschke M; Hynes NE; Groner B
Gene; 1995 Jun; 159(1):73-80. PubMed ID: 7607575
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells.
Wang L; Liu B; Schmidt M; Lu Y; Wels W; Fan Z
Prostate; 2001 Apr; 47(1):21-8. PubMed ID: 11304726
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins.
Jeschke M; Wels W; Dengler W; Imber R; Stöcklin E; Groner B
Int J Cancer; 1995 Mar; 60(5):730-9. PubMed ID: 7860149
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
Schmidt M; Wels W
Br J Cancer; 1996 Sep; 74(6):853-62. PubMed ID: 8826849
[TBL] [Abstract][Full Text] [Related]
10. Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor.
Schmidt M; Vakalopoulou E; Schneider DW; Wels W
Br J Cancer; 1997; 75(11):1575-84. PubMed ID: 9184171
[TBL] [Abstract][Full Text] [Related]
11. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors.
Schmidt M; Maurer-Gebhard M; Groner B; Köhler G; Brochmann-Santos G; Wels W
Oncogene; 1999 Mar; 18(9):1711-21. PubMed ID: 10208432
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas.
von Minckwitz G; Harder S; Hövelmann S; Jäger E; Al-Batran SE; Loibl S; Atmaca A; Cimpoiasu C; Neumann A; Abera A; Knuth A; Kaufmann M; Jäger D; Maurer AB; Wels WS
Breast Cancer Res; 2005; 7(5):R617-26. PubMed ID: 16168106
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitivity testing of oral cancer cells treated with a p185neu-specific agent.
Werkmeister R; Fillies T; Brandt B; Groner B; Weis W; Joos U
Eur J Oral Sci; 1999 Oct; 107(5):338-43. PubMed ID: 10515198
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy of schwannoma cells in immunocompetent rats with an erbB2-specific antibody-toxin.
Altenschmidt U; Schmidt M; Groner B; Wels W
Int J Cancer; 1997 Sep; 73(1):117-24. PubMed ID: 9334818
[TBL] [Abstract][Full Text] [Related]
15. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
[TBL] [Abstract][Full Text] [Related]
17. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
Barth S; Huhn M; Wels W; Diehl V; Engert A
Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
[TBL] [Abstract][Full Text] [Related]
18. A variant of exotoxin A that forms potent and specific chemically conjugated immunotoxins.
Chaudry GJ; Fulton RJ; Draper RK
J Biol Chem; 1993 May; 268(13):9437-41. PubMed ID: 8486636
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cell surface antigens as potential targets for recombinant tumor toxins.
Wick B; Groner B
Cancer Lett; 1997 Oct; 118(2):161-72. PubMed ID: 9459206
[TBL] [Abstract][Full Text] [Related]
20. Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins.
Spyridonidis A; Schmidt M; Bernhardt W; Papadimitriou A; Azemar M; Wels W; Groner B; Henschler R
Blood; 1998 Mar; 91(5):1820-7. PubMed ID: 9473251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
